PILOT, OPEN-LABEL, RANDOMIZED,REPEATED DOSE, 4-WAY CROSS-OVER, CLINICAL PHARMACOLOGY STUDY OF BECLOMETHASONE DIPROPIONATE (CLENIL MODULITE) 250 microg HFA pMDI USING THE AEROCHAMBER PLUS SPACER DEVICE VERSUS THE VOLUMATIC SPACER DEVICE WITHOUT OR WITH CHARCOAL BLOCK IN ASTHMATIC ADULTS PATIENTS

Trial Profile

PILOT, OPEN-LABEL, RANDOMIZED,REPEATED DOSE, 4-WAY CROSS-OVER, CLINICAL PHARMACOLOGY STUDY OF BECLOMETHASONE DIPROPIONATE (CLENIL MODULITE) 250 microg HFA pMDI USING THE AEROCHAMBER PLUS SPACER DEVICE VERSUS THE VOLUMATIC SPACER DEVICE WITHOUT OR WITH CHARCOAL BLOCK IN ASTHMATIC ADULTS PATIENTS

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Beclometasone (Primary)
  • Indications Asthma
  • Focus Pharmacokinetics
  • Sponsors Chiesi Farmaceutici
  • Most Recent Events

    • 21 Dec 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Jun 2011 New trial record
    • 10 May 2011 Planned End Date changed from 1 Jun 2011 to 28 Jul 2011 as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top